Literature DB >> 9472637

Aberrant FHIT transcripts in hepatocellular carcinomas.

Y J Chen1, P H Chen, J G Chang.   

Abstract

To study abnormalities of the FHIT gene in human hepatocellular carcinoma (HCC), eight liver cancer cell lines, 18 matched tumorous and non-tumorous tissues from patients with HCC and three normal liver tissues were analysed by microsatellite polymorphism analysis and reverse transcription of FHIT mRNA followed by polymerase chain reaction (PCR) amplification and sequencing of the products. No loss of heterozygosity at chromosome 3p14.2 as defined by markers D3S1300 and D3S1312 was detected in any of the specimens. In addition, a normal transcript of the gene without any sequence change was found to be expressed in all the cell lines, 17 of the 18 tumorous and all 21 non-tumorous liver tissues tested. Although five out of eight liver cancer cell lines (62.5%), 12 out of 18 HCC tissues (66.7%) and 8 out of 18 paired non-tumorous liver tissues (44.4%) displayed abnormal faint bands of smaller size, sequence analysis revealed that they were aberrant FHIT transcripts lacking three or more exons and might represent alternatively spliced transcripts only. In conclusion, these studies indicate that abnormalities of the FHIT gene transcripts occur in a fairly high frequency of tumorous and non-tumorous liver tissues. However, it might not be causally related to the hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472637      PMCID: PMC2151291          DOI: 10.1038/bjc.1998.66

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Location of dinucleoside triphosphatase in the matrix space of rat liver mitochondria.

Authors:  D Bernet; R M Pinto; A Sillero; J C Cameselle
Journal:  FEBS Lett       Date:  1991-06-03       Impact factor: 4.124

2.  Structure and expression of the human FHIT gene in normal and tumor cells.

Authors:  T Druck; P Hadaczek; T B Fu; M Ohta; Z Siprashvili; R Baffa; M Negrini; K Kastury; M L Veronese; D Rosen; J Rothstein; P McCue; M G Cotticelli; H Inoue; C M Croce; K Huebner
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

3.  Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.

Authors:  R P Beasley; L Y Hwang; C C Lin; C S Chien
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

4.  Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Authors:  J Fogh; W C Wright; J D Loveless
Journal:  J Natl Cancer Inst       Date:  1977-02       Impact factor: 13.506

5.  Hereditary renal-cell carcinoma associated with a chromosomal translocation.

Authors:  A J Cohen; F P Li; S Berg; D J Marchetto; S Tsai; S C Jacobs; R S Brown
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

6.  Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.

Authors:  D P Aden; A Fogel; S Plotkin; I Damjanov; B B Knowles
Journal:  Nature       Date:  1979-12-06       Impact factor: 49.962

7.  Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B.

Authors:  F Boldog; R M Gemmill; J West; M Robinson; L Robinson; E Li; J Roche; S Todd; B Waggoner; R Lundstrom; J Jacobson; M R Mullokandov; H Klinger; H A Drabkin
Journal:  Hum Mol Genet       Date:  1997-02       Impact factor: 6.150

8.  Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma.

Authors:  I Doi
Journal:  Gan       Date:  1976-02

9.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.

Authors:  H Nakabayashi; K Taketa; K Miyano; T Yamane; J Sato
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

10.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

View more
  7 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

2.  Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.

Authors:  Po Zhao; Wu Liu; Ya-Li Lu
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

3.  Fragile histidine triad gene alterations are not essential for hepatocellular carcinoma development in South Korea.

Authors:  Chang-Woo Nam; Jung-Woo Shin; Neung-Hwa Park
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

4.  Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands.

Authors:  H Nagel; R Laskawi; H Eiffert; T Schlott
Journal:  Mol Pathol       Date:  2003-08

5.  Loss of fragile histidine triad protein in human hepatocellular carcinoma.

Authors:  Po Zhao; Xin Song; Yuan-Yuan Nin; Ya-Li Lu; Xiang-Hong Li
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

6.  Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia.

Authors:  T Schlott; K Ahrens; I Ruschenburg; S Reimer; H Hartmann; M Droese
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Association of FHIT expression and FHIT gene hypermethylation with liver cancer risk: a PRISMA-compliant meta-analysis.

Authors:  Yaping Zhang; Xiao Xu; Zhiliang Chen; Zhenhua Zhao
Journal:  Onco Targets Ther       Date:  2017-06-20       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.